GlassScriptPhysician profile
Cherish Van Schaik
NPI 1295164697
$3,717.46
in general payments reported to CMS, 2019-2025
34 companies · $58.28 in 2025
The $58.28 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,845 · 2022: $922 · 2023: $892 · 2025: $58.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.76 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.99 | 2021-2023 | |
| Novo Nordisk INC | $590.20 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceuticals, INC. | $346.73 | 2021 | |
| Esperion Therapeutics, INC. | $272.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.91 | 2022-2023 | |
| Abbott Laboratories | $144.59 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $135.48 | 2021-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $130.23 | 2021 | |
| Pfizer INC. | $121.82 | 2021-2022 | |
| Axsome Therapeutics, INC. | $106.42 | 2023 | Auvelity |
| Sanofi-Aventis U.S. LLC | $95.05 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.31 | 2022 | |
| Astellas Pharma US INC | $64.77 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.70 | 2021-2025 | |
| Amarin Pharma, INC. | $53.43 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $52.14 | 2022 | |
| Lilly USA, LLC | $49.26 | 2021-2023 | Mounjaro |
| Horizon Therapeutics Plc | $44.55 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $41.18 | 2021-2022 | |
| Halozyme INC | $34.94 | 2023 | |
| Glaxosmithkline, LLC. | $28.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.59 | 2022-2023 | |
| Exact Sciences Corporation | $25.78 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $25.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $20.33 | 2023 | Ajovy |
| Otsuka America Pharmaceutical, INC. | $18.28 | 2023 | Rexulti |
| Eisai INC. | $17.79 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.80 | 2021 | |
| Phadia US INC. | $16.44 | 2023 | Immunocap |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
| Dexcom, INC. | $13.77 | 2021 | |
| Currax Pharmaceuticals LLC | $13.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.62 | 2021 | |
| Genentech USA, INC. | $7.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherish Van Schaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.